Human rhinovirus capsid dynamics is controlled by canyon flexibility

Nichole Reisdorph, John J. Thomas, Umesh Katpally, Elaine Chase, Ken Harris, Gary Siuzdak, Thomas Smith

Research output: Contribution to journalArticle

53 Citations (Scopus)

Abstract

Quantitative enzyme accessibility experiments using nano liquid chromatography electrospray mass spectrometry combined with limited proteolysis and isotope-labeling was used to examine the dynamic nature of the human rhinovirus (HRV) capsid in the presence of three antiviral compounds, a neutralizing Fab, and drug binding cavity mutations. Using these methods, it was found that the antivirals WIN 52084 and picovir (pleconaril) stabilized the capsid, while dansylaziridine caused destabilization. Site-directed mutations in the drug-binding cavity were found to stabilize the HRV14 capsid against proteolytic digestion in a manner similar to WIN 52084 and pleconaril. Antibodies that bind to the NIm-IA antigenic site and penetrate the canyon were also observed to protect the virion against proteolytic cleavage. These results demonstrate that quantifying the effects of antiviral ligands on protein "breathing" can be used to compare their mode of action and efficacy. In this case, it is apparent that hydrophobic antiviral agents, antibodies, or mutations in the canyon region block viral breathing. Therefore, these studies demonstrate that mobility in the canyon region is a major determinant in capsid breathing.

Original languageEnglish (US)
Pages (from-to)34-44
Number of pages11
JournalVirology
Volume314
Issue number1
DOIs
StatePublished - Sep 15 2003
Externally publishedYes

Fingerprint

Rhinovirus
Capsid
Antiviral Agents
Respiration
Mutation
Isotope Labeling
Antibodies
Liquid Chromatography
Pharmaceutical Preparations
Virion
Proteolysis
Digestion
Mass Spectrometry
Ligands
Enzymes
pleconaril
Proteins

Keywords

  • Mass spectrometry
  • Rhinovirus
  • Virus maturation

ASJC Scopus subject areas

  • Virology
  • Infectious Diseases

Cite this

Reisdorph, N., Thomas, J. J., Katpally, U., Chase, E., Harris, K., Siuzdak, G., & Smith, T. (2003). Human rhinovirus capsid dynamics is controlled by canyon flexibility. Virology, 314(1), 34-44. https://doi.org/10.1016/S0042-6822(03)00452-5

Human rhinovirus capsid dynamics is controlled by canyon flexibility. / Reisdorph, Nichole; Thomas, John J.; Katpally, Umesh; Chase, Elaine; Harris, Ken; Siuzdak, Gary; Smith, Thomas.

In: Virology, Vol. 314, No. 1, 15.09.2003, p. 34-44.

Research output: Contribution to journalArticle

Reisdorph, N, Thomas, JJ, Katpally, U, Chase, E, Harris, K, Siuzdak, G & Smith, T 2003, 'Human rhinovirus capsid dynamics is controlled by canyon flexibility', Virology, vol. 314, no. 1, pp. 34-44. https://doi.org/10.1016/S0042-6822(03)00452-5
Reisdorph N, Thomas JJ, Katpally U, Chase E, Harris K, Siuzdak G et al. Human rhinovirus capsid dynamics is controlled by canyon flexibility. Virology. 2003 Sep 15;314(1):34-44. https://doi.org/10.1016/S0042-6822(03)00452-5
Reisdorph, Nichole ; Thomas, John J. ; Katpally, Umesh ; Chase, Elaine ; Harris, Ken ; Siuzdak, Gary ; Smith, Thomas. / Human rhinovirus capsid dynamics is controlled by canyon flexibility. In: Virology. 2003 ; Vol. 314, No. 1. pp. 34-44.
@article{b762f2938b794f479f38a333a8489fe7,
title = "Human rhinovirus capsid dynamics is controlled by canyon flexibility",
abstract = "Quantitative enzyme accessibility experiments using nano liquid chromatography electrospray mass spectrometry combined with limited proteolysis and isotope-labeling was used to examine the dynamic nature of the human rhinovirus (HRV) capsid in the presence of three antiviral compounds, a neutralizing Fab, and drug binding cavity mutations. Using these methods, it was found that the antivirals WIN 52084 and picovir (pleconaril) stabilized the capsid, while dansylaziridine caused destabilization. Site-directed mutations in the drug-binding cavity were found to stabilize the HRV14 capsid against proteolytic digestion in a manner similar to WIN 52084 and pleconaril. Antibodies that bind to the NIm-IA antigenic site and penetrate the canyon were also observed to protect the virion against proteolytic cleavage. These results demonstrate that quantifying the effects of antiviral ligands on protein {"}breathing{"} can be used to compare their mode of action and efficacy. In this case, it is apparent that hydrophobic antiviral agents, antibodies, or mutations in the canyon region block viral breathing. Therefore, these studies demonstrate that mobility in the canyon region is a major determinant in capsid breathing.",
keywords = "Mass spectrometry, Rhinovirus, Virus maturation",
author = "Nichole Reisdorph and Thomas, {John J.} and Umesh Katpally and Elaine Chase and Ken Harris and Gary Siuzdak and Thomas Smith",
year = "2003",
month = "9",
day = "15",
doi = "10.1016/S0042-6822(03)00452-5",
language = "English (US)",
volume = "314",
pages = "34--44",
journal = "Virology",
issn = "0042-6822",
publisher = "Academic Press Inc.",
number = "1",

}

TY - JOUR

T1 - Human rhinovirus capsid dynamics is controlled by canyon flexibility

AU - Reisdorph, Nichole

AU - Thomas, John J.

AU - Katpally, Umesh

AU - Chase, Elaine

AU - Harris, Ken

AU - Siuzdak, Gary

AU - Smith, Thomas

PY - 2003/9/15

Y1 - 2003/9/15

N2 - Quantitative enzyme accessibility experiments using nano liquid chromatography electrospray mass spectrometry combined with limited proteolysis and isotope-labeling was used to examine the dynamic nature of the human rhinovirus (HRV) capsid in the presence of three antiviral compounds, a neutralizing Fab, and drug binding cavity mutations. Using these methods, it was found that the antivirals WIN 52084 and picovir (pleconaril) stabilized the capsid, while dansylaziridine caused destabilization. Site-directed mutations in the drug-binding cavity were found to stabilize the HRV14 capsid against proteolytic digestion in a manner similar to WIN 52084 and pleconaril. Antibodies that bind to the NIm-IA antigenic site and penetrate the canyon were also observed to protect the virion against proteolytic cleavage. These results demonstrate that quantifying the effects of antiviral ligands on protein "breathing" can be used to compare their mode of action and efficacy. In this case, it is apparent that hydrophobic antiviral agents, antibodies, or mutations in the canyon region block viral breathing. Therefore, these studies demonstrate that mobility in the canyon region is a major determinant in capsid breathing.

AB - Quantitative enzyme accessibility experiments using nano liquid chromatography electrospray mass spectrometry combined with limited proteolysis and isotope-labeling was used to examine the dynamic nature of the human rhinovirus (HRV) capsid in the presence of three antiviral compounds, a neutralizing Fab, and drug binding cavity mutations. Using these methods, it was found that the antivirals WIN 52084 and picovir (pleconaril) stabilized the capsid, while dansylaziridine caused destabilization. Site-directed mutations in the drug-binding cavity were found to stabilize the HRV14 capsid against proteolytic digestion in a manner similar to WIN 52084 and pleconaril. Antibodies that bind to the NIm-IA antigenic site and penetrate the canyon were also observed to protect the virion against proteolytic cleavage. These results demonstrate that quantifying the effects of antiviral ligands on protein "breathing" can be used to compare their mode of action and efficacy. In this case, it is apparent that hydrophobic antiviral agents, antibodies, or mutations in the canyon region block viral breathing. Therefore, these studies demonstrate that mobility in the canyon region is a major determinant in capsid breathing.

KW - Mass spectrometry

KW - Rhinovirus

KW - Virus maturation

UR - http://www.scopus.com/inward/record.url?scp=0141792174&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0141792174&partnerID=8YFLogxK

U2 - 10.1016/S0042-6822(03)00452-5

DO - 10.1016/S0042-6822(03)00452-5

M3 - Article

VL - 314

SP - 34

EP - 44

JO - Virology

JF - Virology

SN - 0042-6822

IS - 1

ER -